Explore every aspect of life with kidney disease
A systematic review comparing multiple anti-osteoporosis medications for postoperative re-fracture, hip BMD, and function/pain after hip fragility fracture found time- and outcome-specific…
A systematic review and meta-analysis compared multiple drug classes in type 1 diabetes (T1DM) patients for kidney markers and safety; results showed an overall reduction in urine…
A systematic review found limited and inconsistent evidence on the effects of SGLT2 inhibitors on bone health in CKD patients, with particularly scarce data in advanced CKD populations [1].
A systematic review compared CKD cases with and without CUA and identified multiple clinical and laboratory factors associated with CUA occurrence, but mechanisms and causality remain not…
A single-arm meta-analysis of diabetic patients with biopsy-proven MASH found SGLT2 inhibitors were associated with improvements in multiple liver, metabolic, and histologic markers versus…
A systematic review including two randomized controlled trials found teriparatide to be associated with improvements in bone mineral density, but the evidence and safety data remain…
This summary is based on a network meta-analysis that included 27 randomized controlled trials (total n=965) comparing two sequences in concurrent training—aerobic→resistance (CART) versus…
This systematic review and meta-analysis summarizes 36 studies reporting factors associated with the probability of remission of type 2 diabetes (T2DM), noting that the direction of the BMI…
A UK multicenter double-blind feasibility trial compared Anakinra with intramuscular methylprednisolone for gout flares in people with chronic kidney disease; the study reported recruitment…
This summary compiles the 2026 joint guidance, describing when to consider resmetirom or semaglutide, how to choose between them, and key monitoring points in non-cirrhotic MASH with…
A systematic review and meta-analysis of randomized trials found that GLP-1 receptor agonists in CKD patients, predominantly with type 2 diabetes, were associated with lower rates of major…
本系統性回顧與統合分析檢視既存慢性腎臟病（CKD）患者在接受尿路鏡/腎內逆行手術後的腎功能變化，結果顯示整體無顯著惡化，但證據等級很低且異質性高，需謹慎解讀。[1]
A French multicenter randomized trial comparing standard therapy ± bortezomib showed no significant efficacy difference, but the combination group had more serious adverse events.[1]
A systematic review and random-effects meta-analysis showed MASLD and higher liver fibrosis risk are significantly associated with atrial fibrillation (AF) recurrence after catheter…
Add Beyond CKD to your home screen
Open it like an app, and read articles and tools you have visited even when offline.